These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26166017)

  • 1. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease.
    Benson VS; Müllerová H; Vestbo J; Wedzicha JA; Patel A; Hurst JR;
    Respir Med; 2015 Sep; 109(9):1147-54. PubMed ID: 26166017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
    Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
    Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
    Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    Sigterman KE; van Pinxteren B; Bonis PA; Lau J; Numans ME
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD002095. PubMed ID: 23728637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2000; (2):CD002095. PubMed ID: 10796857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2001; (4):CD002095. PubMed ID: 11687139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastro-oesophageal reflux disease increases the risk of intensive care unit admittance and mechanical ventilation use among patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.
    Tsai CL; Lin YH; Wang MT; Chien LN; Jeng C; Chian CF; Perng WC; Chiang CH; Chiou HY
    Crit Care; 2015 Mar; 19(1):110. PubMed ID: 25887791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002095. PubMed ID: 15495027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastro-oesophageal reflux disease (GORD) in Australian general practice patients.
    Miller G; Wong C; Pollack A
    Aust Fam Physician; 2015 Oct; 44(10):701-4. PubMed ID: 26484482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes.
    Quinlivan A; Neuen D; Hansen D; Stevens W; Ross L; Ferdowsi N; Proudman SM; Walker JG; Sahhar J; Ngian GS; Apostolopoulos D; Host LV; Major G; Basnayake C; Morrisroe K; Nikpour M
    Arthritis Res Ther; 2024 Jun; 26(1):124. PubMed ID: 38918847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD.
    Baumeler L; Papakonstantinou E; Milenkovic B; Lacoma A; Louis R; Aerts JG; Welte T; Kostikas K; Blasi F; Boersma W; Torres A; Rohde GG; Boeck L; Rakic J; Scherr A; Tamm M; Stolz D
    Respirology; 2016 Jul; 21(5):883-90. PubMed ID: 26970108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation.
    Terada K; Muro S; Sato S; Ohara T; Haruna A; Marumo S; Kinose D; Ogawa E; Hoshino Y; Niimi A; Terada T; Mishima M
    Thorax; 2008 Nov; 63(11):951-5. PubMed ID: 18535116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of gastro-oesophageal reflux disease in patients with mild-to-moderate chronic obstructive pulmonary disease in India.
    Kamble NL; Khan NA; Kumar N; Nayak HK; Daga MK
    Respirology; 2013 Apr; 18(3):463-7. PubMed ID: 23062059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease.
    Ingebrigtsen TS; Marott JL; Vestbo J; Nordestgaard BG; Hallas J; Lange P
    Respirology; 2015 Jan; 20(1):101-7. PubMed ID: 25297724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of gastroesophageal reflux symptoms in exacerbations of COPD.
    Rascon-Aguilar IE; Pamer M; Wludyka P; Cury J; Coultas D; Lambiase LR; Nahman NS; Vega KJ
    Chest; 2006 Oct; 130(4):1096-101. PubMed ID: 17035443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants: a national survey.
    Bell JC; Schneuer FJ; Harrison C; Trevena L; Hiscock H; Elshaug AG; Nassar N
    Arch Dis Child; 2018 Jul; 103(7):660-664. PubMed ID: 29472195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors use is associated with a lower risk of acute exacerbation and mortality in patients with coexistent COPD and GERD.
    Su VY; Liao HF; Perng DW; Chou YC; Hsu CC; Chou CL; Chang YL; Yen JC; Chen TJ; Chou TC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2907-2915. PubMed ID: 30275689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
    Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
    Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: A post hoc analysis of the 2007 national health and wellness survey.
    Toghanian S; Johnson DA; Stålhammar NO; Zerbib F
    Clin Drug Investig; 2011 Oct; 31(10):703-15. PubMed ID: 21756007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.